Mehdi Benamar

Dr. Mehdi Benamar


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Immunity
Verified
Journal Article
Closed access
JTJacob A. Turner
Jacob A. Turner
ESEmmanuel Stephen-Victor
Emmanuel Stephen-Victor
SWSen Wang
Sen Wang
MRMagali Noval Rivas
Magali Noval Rivas
AAAzza Abdel-Gadir
Azza Abdel-Gadir
TCTalal A. Chatila
Talal A. Chatila

14 September 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
TSThomas Secher
Thomas Secher
SKSahar Kassem
Sahar Kassem
MBMehdi Benamar
Mehdi Benamar
IBIsabelle Bernard
Isabelle Bernard
MBMichele Boury
Michele Boury
Abdelhadi SaoudiAbdelhadi Saoudi
Abdelhadi Saoudi
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) with an increasing incidence in developed countries. Recent reports suggest that modulation of the gut microbiota might be one promising therapy for MS. Here, we investigated whether the probiotic Escherichia coli strain Nissle 1917 (ECN) could modulate the outcome of experimental autoimmune encephalomyelitis (EAE), a murine model of MS. We evidenced that daily oral treatment with ECN, but not with the archetypal K12 E. coli strain MG1655, reduced the severity of EAE induced by immunization with the MOG35-55 peptide. This beneficial effect was associated with a decreased secretion of IFN-g and an increased production of the anti-inflammatory cytokine IL-10 by autoreactive CD4 T cells, both in peripheral lymph nodes and CNS. Interestingly, ECN-treated mice exhibited increased numbers of MOG-specific CD4+ T cells in the periphery contrasting with severely reduced numbers in the CNS, suggesting that ECN might affect T cells migration from the periphery to the CNS through a modulation of their activation and/or differentiation. In addition, we demonstrated that EAE is associated with a profound defect in the intestinal barrier function and that treatment with ECN, but not with MG1655, repaired intestinal permeability dysfunction. Collectively, our data reveal that EAE induces a disruption of the intestinal homeostasis and that ECN protects from disease and restores the intestinal barrier function.

1 June 2021 in Immunity
Verified
Journal Article
Closed access
Hani HarbHani Harb
Hani Harb
MBMehdi Benamar
Mehdi Benamar
PLPeggy S. Lai
Peggy S. Lai
PCPaola Contini
Paola Contini
JGJason W. Griffith
Jason W. Griffith
TCTalal A. Chatila
Talal A. Chatila

1 October 2016 in Immunity
Verified
Journal Article
Closed access
CSCaroline Stienne
Caroline Stienne
MMMichaël F. Michieletto
Michaël F. Michieletto
MBMehdi Benamar
Mehdi Benamar
NCNadège Carrié
Nadège Carrié
IBIsabelle Bernard
Isabelle Bernard
ADAnne S. Dejean
Anne S. Dejean

11 October 2021 in iScience
Verified
Journal Article
Open access
VPValentina Poli
Valentina Poli
VMVictor Pui-Yan Ma
Victor Pui-Yan Ma
MGMarco Di Gioia
Marco Di Gioia
ABAchille Broggi
Achille Broggi
MBMehdi Benamar
Mehdi Benamar
IZIvan Zanoni
Ivan Zanoni
Neutrophil extracellular traps (NETs) have been implicated in the pathogenesis of acute respiratory distress syndrome (ARDS) driven by viruses or bacteria, as well as in numerous immune-mediated disorders. Histone citrullination by the enzyme peptidylarginine deiminase 4 (PAD4) and the consequent decondensation of chromatin are hallmarks in the induction of NETs. Nevertheless, additional histone modifications that may govern NETosis are largely overlooked. Herein, we show that histone deacetylases (HDACs) play critical roles in driving NET formation in human and mouse neutrophils. HDACs belonging to the zinc-dependent lysine deacetylases family are necessary to deacetylate histone H3, thus allowing the activity of PAD4 and NETosis. Of note, HDAC inhibition in mice protects against microbial-induced pneumonia and septic shock, decreasing NETosis and inflammation. Collectively, our findings illustrate a new fundamental step that governs the release of NETs and points to HDAC inhibitors as therapeutic agents that may be used to protect against ARDS and sepsis.

22 January 2025 in Nature
Verified
Journal Article
Closed access
PDF file
ESEmmanuel Stephen-Victor
Emmanuel Stephen-Victor
GKGavin A. Kuziel
Gavin A. Kuziel
MMMonica Martinez-Blanco
Monica Martinez-Blanco
BJBat-Erdene Jugder
Bat-Erdene Jugder
MBMehdi Benamar
Mehdi Benamar
TCTalal A. Chatila
Talal A. Chatila